Differences Between Ulcerative Colitis and Crohn's Disease

Parts of intestine affected by ulcerative colitis and Crohn's
Lars Neumann / Getty Images

The two primary forms of inflammatory bowel disease (IBD)—Crohn's disease and ulcerative colitis—are often lumped together. But, some of their characteristics are very different.


These diseases share many symptoms, but their treatments, both medical and surgical, are not exactly the same. In many cases, a trained gastroenterologist (through the use of various test results) can determine whether a case of IBD is either Crohn's disease or ulcerative colitis.


What Causes Ulcerative Colitis?

However, there are cases where the diagnosis of one form of IBD over the other is very difficult. At times, a final diagnosis is possible only after an event during the course of the disease or its treatment makes the form of IBD readily apparent.

Patients with IBD may be very confused as to the differences between these diseases. As with any chronic condition, education is an important tool to become an active participant in one's own treatment plan.

If your diagnosis isn't firm, don't panic. In some people, it can take time to determine if the IBD is more like Crohn's disease or more like ulcerative colitis. In about 5-20% of cases, people are diagnosed as having indeterminate colitis (IC).

IBD is becoming increasingly treatable and there are now many medications in the arsenal that are helping people with all forms get greater control over their disease. The main differences between ulcerative colitis and Crohn's disease are described below.

Ulcerative Colitis
  • Pain in lower left abdomen

  • Bleeding common during bowel movements

  • Inflammation usually only in the colon

  • Continuous inflammation, not patchy

  • Colon wall thinned

  • Granulomas not present

  • Ulcers only in mucous lining of colon

  • Complications less frequent

  • Seen more often in non-smokers

Crohn's Disease
  • Pain in lower right abdomen

  • Bleeding not common during bowel movements

  • Inflammation anywhere in digestive tract

  • Inflammation in one or more patches

  • Colon has cobblestone appearance and thickened wall

  • Granulomas often present

  • Ulcers in colon are deeper

  • Complications more frequent

  • Smoking can worsen condition


Many symptoms of ulcerative colitis and Crohn's disease are similar, but there are some subtle differences.

  • Ulcerative colitis patients tend to have pain in the lower left part of the abdomen, while Crohn's disease patients commonly (but not always) experience pain in the lower right abdomen.
  • With ulcerative colitis, bleeding from the rectum during bowel movements is very common; bleeding is much less common in patients with Crohn's disease.

Location of Inflammation

  • In Crohn's disease, the location of the inflammation may occur anywhere along the digestive tract from the mouth to the anus.
  • In ulcerative colitis, the large intestine (colon) is typically the only site that is affected. However, in some people with ulcerative colitis the last section of the small intestine, the ileum, may also show inflammation.

Pattern of Inflammation

The pattern that each form of IBD takes in the digestive tract is very distinct.

  • Ulcerative colitis tends to be continuous throughout the inflamed areas. In many cases, ulcerative colitis begins in the rectum or sigmoid colon and spreads up through the colon as the disease progresses.
  • In Crohn's disease, the inflammation may occur in patches in one or more organs in the digestive system. For instance, a diseased section of colon may appear between two healthy sections.


During a colonoscopy or sigmoidoscopy, a physician can view the actual inside of the colon.

  • In a colon that has Crohn's disease activity, the colon wall may be thickened and, because of the intermittent pattern of diseased and healthy tissue, may have a "cobblestone" appearance.
  • In ulcerative colitis, the colon wall is thinner and shows continuous inflammation with no patches of healthy tissue in the diseased section.


Granulomas are inflamed cells that become lumped together to form a lesion. Granulomas are present in Crohn's disease, but not in ulcerative colitis. Therefore, when they are found in tissue samples taken from an inflamed section of the digestive tract, they are a good indicator that Crohn's disease is the correct diagnosis.


  • In ulcerative colitis, the mucous lining of the large intestine is ulcerated. These ulcers do not extend beyond this inner lining.
  • In Crohn's disease, the ulceration is deeper and may extend into all the layers of the bowel wall.


In Crohn's disease, strictures, fissures, and fistulas are not uncommon complications. These conditions are less frequently found in cases of ulcerative colitis.


One of the more confounding aspects of IBD is its interaction with cigarette smoking or tobacco.

  • Smoking is associated with a worse disease course in Crohn's disease patients and may increase the risk of relapses and surgery.
  • For some people with ulcerative colitis, smoking has a protective effect, though smoking is NOT recommended due to its significant health risks. Ulcerative colitis is often called a "disease of non-smokers."



In many cases, the drugs used to treat Crohn's disease and ulcerative colitis are similar. However, there are some medications that are more effective for one form of IBD over the other.

Historically, the mainstays of treatment for ulcerative colitis include 5-ASA medications and corticosteroids. The 5-ASA drugs are typically not used to treat Crohn's disease when it only involves the small intestine (though corticosteroids are).

That said, for people who have moderate to severe ulcerative colitis, guidelines no longer recommend using a step-up approach (5-ASA medications first, and then biologic medications if that approach fails). Instead, it's recommended that biologic medications (with or without a thiopurine medication) be used as first-line therapy.

Some medications are only approved to treat one form of IBD or the other. For instance, Cimzia (certolizumab pegol) is only approved to treat Crohn's disease and Colazal (balsalazide disodium) is only approved to treat ulcerative colitis.

Other newer drugs (biologics), including Humira (adalimumab) and Entyvio (vedolizumab), are approved for both Crohn's disease and ulcerative colitis.


For patients living with Crohn's disease, surgery to remove diseased sections of bowel may provide some relief from symptoms, but the disease tends to recur. Because the inflammation only occurs in the large intestine in ulcerative colitis, the removal of that organ (called a colectomy) is considered a "cure."

Removing only part of the colon is not usually done with ulcerative colitis patients, as the disease will recur in the portion of the colon that is left. After a colectomy, an ulcerative colitis patient may have an ileostomy or one of several types of internal pouches created from the healthy small intestine.

Internal pouches are not typically not created in Crohn's disease patients who must undergo colectomy, because the Crohn's disease may occur in the pouch.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectivesWorld J Gastroenterol. 2015;21(1):21–46. doi:10.3748/wjg.v21.i1.21

  2. Faecal Calprotectin Testing for Differentiating amongst Inflammatory and Non-Inflammatory Bowel Diseases: Systematic Review and Economic Evaluation. NIHR Journals Library; 2013.

  3. Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatmentsJ Inflamm Res. 2014;7:113–120. Published 2014 Jun 23. doi:10.2147/JIR.S65979

  4. Kilcoyne A, Kaplan JL, Gee MS. Inflammatory bowel disease imaging: Current practice and future directionsWorld J Gastroenterol. 2016;22(3):917–932. doi:10.3748/wjg.v22.i3.917

  5. National Center for Biotechnology Information Genes and Disease. Crohn's disease

  6. Bastida G, Beltrán B. Ulcerative colitis in smokers, non-smokers and ex-smokersWorld J Gastroenterol. 2011;17(22):2740–2747. doi:10.3748/wjg.v17.i22.2740

  7. Probert C. Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemmaTherap Adv Gastroenterol. 2013;6(1):33–38. doi:10.1177/1756283X12461395

  8. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020. 158(5):1450-1461. doi:10.1053/j.gastro.2020.01.006

  9. Alexander W. Digestive disease week and american diabetes association: digestive disease weekP T. 2008;33(9):546–549.

  10. Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectivesJ Inflamm Res. 2018;11:215–226. Published 2018 May 16. doi:10.2147/JIR.S165330

  11. Hwang JM, Varma MG. Surgery for inflammatory bowel diseaseWorld J Gastroenterol. 2008;14(17):2678–2690. doi:10.3748/wjg.14.2678

  12. Braveman JM, Schoetz DJ, Marcello PW, et al. The fate of the ileal pouch in patients developing Crohn's disease. Dis Colon Rectum. 2004;47(10):1613-9. doi:10.1007/s10350-004-0645-5